Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Primary Purpose
Solid Tumor, Unspecified, Adult
Status
Recruiting
Phase
Phase 1
Locations
Taiwan
Study Type
Interventional
Intervention
MPB-1734
Sponsored by

About this trial
This is an interventional treatment trial for Solid Tumor, Unspecified, Adult
Eligibility Criteria
Inclusion Criteria:
- Signed informed consent in the local language prior to any study-mandated procedure.
- Male or female patients at least 18 years of age, at the time of informed consent.
- Male or nonpregnant and nonlactating female patients with pathologically confirmed, measurable solid tumor lesions (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) that are unresectable, and standard therapy able to provide clinical benefit does not exist or is no longer effective.
- Eastern Cooperative Oncology Group Performance Status ≤2.
Patients have recovered from the acute toxicity of previous therapies (peripheral sensory neuropathy recovered to ≤Grade 2) except alopecia, and:
- At least 4 weeks have elapsed since completing surgery, endocrine therapy, tyrosine kinase inhibitor therapy, immunotherapy, radiotherapy, chemotherapy, and/or
- At least 6 weeks have elapsed since completing chemotherapy with nitrosoureas, melphalan, and/or mitomycin C, and/or
- At least 6 weeks have elapsed since completing cranial radiotherapy.
- Life expectancy of greater than 12 weeks.
- Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.
Exclusion Criteria:
- Peripheral sensory neuropathy >Grade 2 (CTCAE version 5.0) at baseline.
- Patients requiring immediate palliative treatment of any kind including surgery and/or radiotherapy.
- Serum bilirubin >1.5× ULN.
- AST and/or ALT >2.5× ULN if no liver involvement, OR AST and/or ALT >5× ULN with liver involvement.
- Serum creatinine >1.5× ULN, and/or a creatinine clearance of <50 mL/min calculated by Cockcroft Gault.
- QTc prolongation defined as a QTc with Framingham correction greater than or equal to 470 ms, or significant electrocardiogram (ECG) abnormalities.
- Known hypersensitivity to taxanes or any excipients of the drug formulation.
- Female patients who are pregnant, breast-feeding, or planning to become pregnant during the study.
- Untreated and/or uncontrolled central nervous system metastases.
- Patients with brain tumors, primary or metastatic.
- Patients taking concomitant medications anticipated to result in drug-drug interactions.
Sites / Locations
- Taipei Veterans General HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
MPB-1734, single arm, dose escalation
Arm Description
intravenous, once per 3 weeks, starting at 10 mg/m˄2
Outcomes
Primary Outcome Measures
Evaluation the the maximum tolerated dose(MTD) by safety data
Number and incidence of (serious) adverse events (AEs) ([S]AEs), including rate of mild, moderate, and severe hypersensitivity reactions, fluid retention, and sensory neuropathy an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle.
Secondary Outcome Measures
Incidence of Treatment-Emergence Adverse Events
Each adverse event will be coded using the Medical Dictionary (version 20.0) system. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).
Maximum observed plasma concentration (Cmax)
Evaluation the change of Cmax
Area under the plasma concentration-time curve (AUC)
Evaluation the change of AUC
Half-life (T1/2)
Evaluation of T1/2
Full Information
NCT ID
NCT04643418
First Posted
November 20, 2020
Last Updated
April 27, 2022
Sponsor
MegaPro Biomedical Co. Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04643418
Brief Title
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Official Title
Phase 1/2a Dose-ranging, Safety, Pharmacokinetics, and Preliminary Efficacy Study of MPB-1734 in Patients With Advanced Solid Tumors in Part 1 and With Selected Solid Tumors in Part 2
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 8, 2022 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MegaPro Biomedical Co. Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.
Detailed Description
This study will occur in two parts, Dose-escalation (Part 1) and Cohort-expansion (Part 2). The main purpose of Part 1 is to determine the doses and dosing schedule of MPB-1734 that is safe and tolerable when given in subjects with certain types of advanced cancer. Part 2 of the study will begin when the Sponsor determines the safe and tolerable doses and dosing schedule from Part 1. The main purpose of Part 2 is to continue to assess the safety and tolerability of the MPB-1734 dose and dosing schedule determined by the Sponsor during Part 1. The preliminary efficacy of MPB-1734 will also be assessed in both Part 1 and Part 2.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor, Unspecified, Adult
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
81 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
MPB-1734, single arm, dose escalation
Arm Type
Experimental
Arm Description
intravenous, once per 3 weeks, starting at 10 mg/m˄2
Intervention Type
Drug
Intervention Name(s)
MPB-1734
Other Intervention Name(s)
DMB025
Intervention Description
Administered once daily in a 21-day cycle
Primary Outcome Measure Information:
Title
Evaluation the the maximum tolerated dose(MTD) by safety data
Description
Number and incidence of (serious) adverse events (AEs) ([S]AEs), including rate of mild, moderate, and severe hypersensitivity reactions, fluid retention, and sensory neuropathy an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle.
Time Frame
Through the end of the first cycle (Days 1-21).
Secondary Outcome Measure Information:
Title
Incidence of Treatment-Emergence Adverse Events
Description
Each adverse event will be coded using the Medical Dictionary (version 20.0) system. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).
Time Frame
Approximately 24 weeks
Title
Maximum observed plasma concentration (Cmax)
Description
Evaluation the change of Cmax
Time Frame
Day 1-Day 2
Title
Area under the plasma concentration-time curve (AUC)
Description
Evaluation the change of AUC
Time Frame
Day 1-Day 2
Title
Half-life (T1/2)
Description
Evaluation of T1/2
Time Frame
Day 1-Day 2
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed informed consent in the local language prior to any study-mandated procedure.
Male or female patients at least 18 years of age, at the time of informed consent.
Male or nonpregnant and nonlactating female patients with pathologically confirmed, measurable solid tumor lesions (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) that are unresectable, and standard therapy able to provide clinical benefit does not exist or is no longer effective.
Eastern Cooperative Oncology Group Performance Status ≤2.
Patients have recovered from the acute toxicity of previous therapies (peripheral sensory neuropathy recovered to ≤Grade 2) except alopecia, and:
At least 4 weeks have elapsed since completing surgery, endocrine therapy, tyrosine kinase inhibitor therapy, immunotherapy, radiotherapy, chemotherapy, and/or
At least 6 weeks have elapsed since completing chemotherapy with nitrosoureas, melphalan, and/or mitomycin C, and/or
At least 6 weeks have elapsed since completing cranial radiotherapy.
Life expectancy of greater than 12 weeks.
Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.
Exclusion Criteria:
Peripheral sensory neuropathy >Grade 2 (CTCAE version 5.0) at baseline.
Patients requiring immediate palliative treatment of any kind including surgery and/or radiotherapy.
Serum bilirubin >1.5× ULN.
AST and/or ALT >2.5× ULN if no liver involvement, OR AST and/or ALT >5× ULN with liver involvement.
Serum creatinine >1.5× ULN, and/or a creatinine clearance of <50 mL/min calculated by Cockcroft Gault.
QTc prolongation defined as a QTc with Framingham correction greater than or equal to 470 ms, or significant electrocardiogram (ECG) abnormalities.
Known hypersensitivity to taxanes or any excipients of the drug formulation.
Female patients who are pregnant, breast-feeding, or planning to become pregnant during the study.
Untreated and/or uncontrolled central nervous system metastases.
Patients with brain tumors, primary or metastatic.
Patients taking concomitant medications anticipated to result in drug-drug interactions.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Summer Liao, MS
Phone
+886-3-5910360
Ext
231
Email
thliao@megaprobio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muh-Hwa Yang, MD
Organizational Affiliation
Taipei Veterans General Hospital, Taiwan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Taipei Veterans General Hospital
City
Taipei
ZIP/Postal Code
112
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Iris Chang
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
We'll reach out to this number within 24 hrs